Showing results (151-160 of 424) with videos related to
Sort By:
Pageof 43
AIDS (London, England)|April 20, 2004
Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infectionNadia Alatrakchi, Vincent Di Martino, Vincent Thibault, et al.Plos One|December 30, 2017
Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recoveryValentina Peta, Chantal Tse, Hugo Perazzo, et al.Liver International : Official Journal of the International Association for the Study of the Liver|April 6, 2006
Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective studyDominique Thabut, Jean-Baptiste Trabut, Julien Massard, et al.Hepatology (Baltimore, Md.)|January 3, 2013
Chronic hepatitis C virus (HCV) disease burden and cost in the United StatesHomie Razavi, Antoine C Elkhoury, Elamin Elbasha, et al.Alimentary Pharmacology & Therapeutics|June 28, 2019
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesityPhilip Newsome, Sven Francque, Stephen Harrison, et al.Plos One|November 20, 2020
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19Thierry Poynard, Olivier Deckmyn, Marika Rudler, et al.Journal of Hepatology|December 3, 2014
Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleedingMarika Rudler, Sarah Mouri, Frédéric Charlotte, et al.Clinical Chemistry and Laboratory Medicine|April 8, 2006
Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scoresGeorges Férard, Annie Piton, Djamila Messous, et al.Alimentary Pharmacology & Therapeutics|December 21, 2018
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosisThierry Poynard, Valentina Peta, Olivier Deckmyn, et al.Plos One|March 9, 2023
Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpointsElias Laurin Meyer, Peter Mesenbrink, Nicholas A Di Prospero, et al.Pageof 43